Evidence map›Paper›PMID 28342058›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.

J F Cueva, S Antolín, L Calvo, I Fernández, M Ramos, L de Paz, J G Mata, R López, M Constenla, E Pérez and 4 more

Open access · hybridAbstract readConsensus Statement
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

J F CuevaOncology Department, Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain. jfcueva@gmail.com.
S AntolínOncology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
L CalvoOncology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
I FernándezOncology Department, Complejo Hospitalario Universitario Vigo, Vigo, Spain.
M RamosOncology Department, Centro Oncológico Galicia, A Coruña, Spain.
L de PazOncology Department, Complejo Hospitalario Universitario Ferrol, Ferrol, Spain.
J G MataOncology Department, Complejo Hospitalario Universitario Ourense, Orense, Spain.
R LópezOncology Department, Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain.
M ConstenlaOncology Department, Complejo Hospitalario Universitario Pontevedra, Pontevedra, Spain.
E PérezOncology Department, Complejo Hospitalario Universitario Ourense, Orense, Spain.
A GonzálezOncology Department, Centro Oncológico Galicia, A Coruña, Spain.
M L PellónOncology Department, Complejo Hospitalario Universitario Ferrol, Ferrol, Spain.
S VarelaOncology Department, Complejo Hospitalario Universitario Lugo, Lugo, Spain.
T LópezCardiology Department, Hospital Universitario La Paz, Madrid, Spain.
Centro Oncológico de Galicia · ESComplejo Hospitalario de Ourense · ESComplejo Hospitalario Universitario de Ferrol · ESComplejo Hospitalario Universitario de Santiago · ESComplexo Hospitalario Universitario A Coruña · ESUniversity Hospital Complex Of Vigo · ESComplejo Hospitalario de Pontevedra · ESHospital Universitario La Paz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This Galician consensus statement is a joint oncologists/cardiologists initiative indented to establish basic recommendations on how to prevent and to manage the cardiotoxicity in breast cancer with the aim of ensuring an optimal cardiovascular care of these patients. A clinical screening of the patients before treatment is recommended to stratify them into a determined risk group based on their intrinsic cardiovascular risk factors and those extrinsic arose from breast cancer therapy, thereby providing individualized preventive and monitoring measures. Suitable initial and ongoing assessments for patients with low and moderate/high risk and planned treatment with anthracyclines and trastuzumab are given; also, measures aimed at preventing and correcting any modifiable risk factor are pointed out .

Indexed as

Antineoplastic AgentsBreast NeoplasmsCardiotoxicityFemaleHumansRisk FactorsAntineoplastic AgentsAnticancer therapiesBreast cancerCardiotoxicityCardiovascular risk factors

Identifiers

PMID28342058
PMCPMC5547178
OpenAlexW2603463623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.